GLP-1/GLP-1RAs have been shown to affect both basal and reward-related feeding, and increase dopamine transporter levels (202, 203)
Apart from subcutaneous injections, PT-141 has also been investigated for its potential use as a nasal spray
This ensures balanced nutrition without requiring calorie counting or complex tracking
Excellence in Economic Development Award function, at the 23rd Indian Achievers Summit on 22nd April 2010 at India Habitat Centre, New Delhi
We do not use capsules for this product that result in delayed release
Common side effects during the adjustment period (typically the first 24 weeks): Mild nausea usually less intense than when first starting a GLP-1 medication Changes in appetite (some patients notice less appetite suppression early on at the starting 0.25 mg dose) Mild stomach discomfort, bloating, or constipation Injection site reactions Side effects that are less likely during the switch (compared to first-time GLP-1 use), but still possible: Significant vomiting less common given prior GLP-1 exposure, but possible Hypoglycemia particularly relevant for type 2 diabetes patients on insulin or sulfonylureas
